The Maybridge line is a comprehensive range of highly innovative and diverse drug-like molecules and compound libraries for traditional drug-discovery screening, as well as fragment-based programs. These products are used by researchers worldwide to accelerate the identification and development of lead compounds for potential new drug therapies.
The Maybridge business, founded by organic chemist Dr. R.J. Bridgewater in 1962, became part of Thermo Fisher in 2002. The Maybridge team continues to build on its strong reputation for innovation, offering a high level of expertise in the design and synthesis of novel compounds and consistently delivering outstanding quality and service to its ever-growing customer base. The Maybridge line now encompasses more than 56,000 pre-plated drug-like screening compounds. These compounds comprise screening collections such as the renowned HitFinder™ and Ro3 Diversity Fragment libraries and an expanding range of highly reactive heterocyclic building blocks.
“We are very proud that after 50 years Maybridge products continue to enable discovery,” said Simon Pearce, product manager for Maybridge and Acros Organics products at Thermo Fisher. “We continue to evolve to better serve our customers and have just completed our move from Tintagel, England to the Thermo Fisher site in Loughborough, where we will further strengthen our core offerings and improve our service to our customers worldwide. Our new location will allow us to leverage the dedicated technical, supply-chain and operational teams that support other world-class Thermo Fisher Scientific chemical product lines.”